A new study supports the potential to repurpose glucagon-like peptide 1 (GLP-1) receptor agonists, used to treat type 2 diabetes and obesity, for dementia prevention. In the phase 2b ELAD clinical trial, adults with early-stage Alzheimer’s disease (AD) taking the GLP-1 receptor agonist liraglutide exhibited slower decline in memory and thinking and experienced less brain …
